Genetic Testing Being Mainstreamed to Consumers—Good or Bad Idea?

May 2018 Vol 9, No 5

Categories:

Commentary
Lillie D. Shockney, RN, BS, MAS, ONN-CG
Program Director and Co-Founder, AONN+; University Distinguished Service Professor of Breast Cancer, Departments of Surgery and Oncology; Administrative Director, The Johns Hopkins Breast Center; Director, Cancer Survivorship Programs at the Sidney Kimmel Cancer Center at Johns Hopkins; Professor, JHU School of Medicine, Departments of Surgery, Oncology, Gynecology & Obstetrics - Baltimore, MD

We all want patients/consumers to have the information they need for reducing their risk of getting breast cancer as well as to be empowered with information so they can embark on shared decision-making with their oncology treatment team. Enabling consumers to get a genetic testing kit for self-collection, with results sent to their home, has now happened, courtesy of the FDA.

This direct-to-consumer issue is serious because ramifications can include unwise decisions that were based on limited information. Given this level of access, patients may assume that if their test is negative for a breast cancer gene mutation, they have no risk of getting cancer; or if their test is positive, that they are doomed to get several types of cancer. So we need to caution our patients about traveling this direct-to-consumer road.

Those navigators involved with community outreach need to explain, at health fairs and other venues, that it is smarter to get genetic counseling from professional individuals certified in genetics counseling rather than taking this test as an opportunity to learn about their genetic status. The test is easy to do; the interpretation of the results is not. It would be terrible to have consumers not get a mammogram because their test was negative. Their family history, other risk factors, and lack of testing for other breast cancer genes may actually point to them being at high risk for getting breast cancer. And what do the test results mean for siblings, offspring, and other family members?

These issues illustrate why genetic testing should not be taken on single-handedly by a patient or consumer. Without professional counseling, testing should not happen.

Related Articles
“Establishing a Successful Navigation Program”: A JONS Exclusive Series
Lillie D. Shockney, RN, BS, MAS, ONN-CG
|
October 2018 Vol 9, NO 10

How do you establish a successful navigation program? The answers are right here in this issue!

Opioid Awareness and the Role of the Cancer Navigator in Management of Malignant Pain
John R. Himberger
|
October 2018 Vol 9, NO 10

The opioid crisis, although not new to the United States, has gained significant attention since the government recognition and subsequent announcement of the problem in 2017.

Journal of Oncology Navigation & Survivorship: Providing an Array of Topics Relevant to Navigators
Lillie D. Shockney, RN, BS, MAS, ONN-CG
|
September 2018 Vol 9, No 9
On behalf of the Editorial Board of the Journal of Oncology Navigation & Survivorship (JONS), it's my pleasure to offer the current issue. Each month, we aim to present navigators with an array of topics relevant to their practice. To achieve our goal, we publish original navigation research, treatment updates, interviews, and navigation best practices. Some highlights from the current issue follow.
Cite this Article

Journal of Oncology Navigation & Survivorship. 2018;9:195.

Last modified: June 11, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code